CBAY Insider Trading Activity and SEC Form 4 Filings
CBAY insider trading summary
No open-market insider purchases or sales of CymaBay Therapeutics, Inc. (CBAY) have been reported on SEC Form 4 in the past 12 months.
Latest CBAY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 12, 2024 | Janet Dorling | Director | Sell | $192K (6,000 @ $31.97) |
| Jan 19, 2024 | Charles McWherter | President of R&D | Sell | $74K (3,125 @ $23.68) |
| Jan 19, 2024 | Charles McWherter | President of R&D | Sell | $197K (8,334 @ $23.68) |
| Jan 19, 2024 | Charles McWherter | President of R&D | Sell | $53K (2,250 @ $23.67) |
| Jan 19, 2024 | Charles McWherter | President of R&D | Sell | $66K (2,778 @ $23.66) |
| Jan 19, 2024 | Charles McWherter | President of R&D | Sell | $45K (1,916 @ $23.66) |
| Jan 16, 2024 | Paul T Quinlan | General Counsel | Sell | $118K (5,000 @ $23.58) |
| Jan 16, 2024 | Daniel Menold | Vice President, Finance | Sell | $236K (10,000 @ $23.58) |
| Jan 10, 2024 | Janet Dorling | Director | Sell | $143K (6,000 @ $23.86) |
| Dec 18, 2023 | Charles McWherter | President of R&D | Sell | $140K (6,504 @ $21.48) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.